127 related articles for article (PubMed ID: 24745158)
1. The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer.
Ekinci T; Ozbay PO; Yiğit S; Yavuzcan A; Uysal S; Soylu F
Ginekol Pol; 2014 Feb; 85(2):121-30. PubMed ID: 24745158
[TBL] [Abstract][Full Text] [Related]
2. Correlation of survivin and MMP9 expressions with prognosis and clinicopathological parameters in surface epithelial ovarian carcinomas.
Kuşku Cabuk F; Yığıt S; Demır L; Cakalağaoğlu F; Tarhan O
Turk Patoloji Derg; 2014; 30(1):30-7. PubMed ID: 24448704
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
4. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of matrix metalloproteinase-2 expression in patients with epithelial ovarian tumor].
Wu X; Li H; Song J
Zhonghua Fu Chan Ke Za Zhi; 2001 Oct; 36(10):621-4. PubMed ID: 16134528
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between bacterial L-form infection, expression of HIF-1α/MMP-9 and vasculogenic mimicry in epithelial ovarian cancer].
Yu L; Wu SW; Zhou L; Song WQ
Sheng Li Xue Bao; 2012 Dec; 64(6):657-65. PubMed ID: 23258329
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Zhou S; Tang L; Wang H; Dai J; Zhang J; Shen L; Ng SW; Berkowitz RS
Gynecol Oncol; 2013 Oct; 131(1):69-76. PubMed ID: 23820113
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
9. Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer.
Vos MC; van der Wurff AA; Bulten J; Kruitwagen R; Feijen H; van Kuppevelt TH; Hendriks T; Massuger LF
Diagn Pathol; 2016 Apr; 11():34. PubMed ID: 27038607
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors.
Ozalp S; Tanir HM; Yalcin OT; Kabukcuoglu S; Oner U; Uray M
Eur J Gynaecol Oncol; 2003; 24(5):417-20. PubMed ID: 14584660
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours.
Kamel H; Abdelazim I; Habib SM; El Shourbagy MAA; Ahmed NS
J Obstet Gynaecol Can; 2010 Jun; 32(6):580-586. PubMed ID: 20569539
[TBL] [Abstract][Full Text] [Related]
12. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao GL; Liu LD; Zou XS; Chen WX
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
15. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
18. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
19. Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer.
Wu X; Li H; Kang L; Li L; Wang W; Shan B
Gynecol Oncol; 2002 Jan; 84(1):126-34. PubMed ID: 11748988
[TBL] [Abstract][Full Text] [Related]
20. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Kamat AA; Fletcher M; Gruman LM; Mueller P; Lopez A; Landen CN; Han L; Gershenson DM; Sood AK
Clin Cancer Res; 2006 Mar; 12(6):1707-14. PubMed ID: 16551853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
